RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
In a regulatory filing, Generex Biotechnology (OTCQB:GNBT) disclosed the receipt of $2M towards its COVID-19 vaccine development initiatives from its Chinese partners taking the total receipts to $3.1M.
In November, the company and its majority-owned subsidiary NuGenerex Immuno-Oncology signed The Ii-Key Innovative Flu Vaccine Development Agreement with a Chinese consortium led by Beijing Youfeng International Consulting Co., Ltd.
Per the agreement, Generex was entitled to a licensing fee of $2.5M upon the successful development of the flu vaccine and receipt of commercial approval from the Chinese regulator.
In December, an extension agreement allowed the company to receive an upfront licensing fee of $5M.
In an update on its COVID-19 vaccine program, Generex said in December, the Ii-Key COVID-19 vaccine with multiple epitopes had the potential to be a complete vaccine and it has filed a trademark application for The Complete Vaccine™.
I-Mab (IMAB +8.5%) announced that it received regulatory approval in China to initiate Phase 1 trial for TJ210/MOR210 monotherapy in patients with advanced solid tumors.
With the approval received from Center for Drug Evaluation (“CDE”) of the China National Medical Products Administration (“NMPA”) for the Investigational New Drug application for TJ210/MOR210, the company is set to advance the monoclonal antibody in a Phase 1 study involving multiple doses.
In the Phase 1 program, TJ210/MOR210 will undergo an open-label dose-escalation study to evaluate the safety, tolerability, and PK/PD and preliminary efficacy of TJ210/MOR210 in subjects with relapsed or refractory advanced solid tumors.
Last month, I-Mab announced that the dosing got underway in the U.S. for a similar Phase 1 trial for the experimental therapy developed by MorphoSys (NASDAQ:MOR).
AbbVie (NYSE:ABBV) and Caribou Biosciences have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (NASDAQ:CAR)-T cell therapeutics.
Caribou will receive $40M in an upfront cash payment and equity investment, along with up to $300M in future development, regulatory, and launch milestones.
Under the multi-year agreement, AbbVie will utilize Caribou’s next-generation Cas12a CRISPR hybrid RNA-DNA (chRDNA) genome editing and cell therapy technologies to research and develop two new CAR-T cell therapies directed to targets specified by AbbVie.
Caribou will conduct certain pre-clinical research, development, and manufacturing activities for the collaboration programs, and AbbVie will reimburse Caribou.
